Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.

NCT01686386 is registered in ClinicalTrials.gov with Gruppo Italiano Studio Linfomi as lead sponsor.

NCT NCT01686386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01686386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.
Lead sponsor
Gruppo Italiano Studio Linfomi
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 28, 2010
Completion date
October 31, 2013
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma